Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-CTLA4 Combined With IL-2 for Metastatic Melanoma
NCT00058279Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose. Started Feb 2003; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00058279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058279.